{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34","upperLimit":"53","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"description":"Percentage of participants who developed relapse or progressive disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.","id":"OG000","title":"Bone Marrow Transplant"}],"paramType":"NUMBER","populationDescription":"The study data was analyzed early after 117 participants had been treated. This was done in order to publish the data and establish a new local standard of care at our institution. Relapse data was not collected on the remaining 25 participants.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Relapse","type":"SECONDARY","unitOfMeasure":"percentage of participants"}